Precision BioSciences, Inc. Stock News

Precision BioSciences is advancing a de-risked gene-editing pipeline with promising clinical data and multi-year cash runway. PBGENE-HBV shows compelling early efficacy and safety, positioning DTIL for a potential breakthrough in functional cures for chronic hepatitis B. DTIL maintains a 2/5 conviction rating due to technical weakness, competitive risks, and the need for cleaner bullish signals...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will deliver an oral presentation at the Hep-DART 2025 meeting, to take place December 7–11, 2025, at the Hilton Hawaiian Village in Honolul...

Precision BioSciences, Inc. ( DTIL ) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B November 11, 2025 8:00 AM EST Company Participants Naresh Tanna - Chief of Staff to CEO & Head of Investor Relations Michael Amoroso - President, CEO & Director Mark Sulkowski Cassie Gorsuch - Chief Scientific Officer John Kelly - CFO & Principal Accounting Office...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has agreed to sell by way of an underwritten offering 10,815,000 shares of its common stock and accompanying warrants to purch...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2025. The presentation incl...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. “Throughout the third quarter, we made strong prog...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the third quarter 2025 and provide a business update on November 3, 2025. About Precision BioSciences, In...

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has been selected to deliver a late-breaking oral presentation at the Liver Meeting® 2025. The oral presentation will feature new PBGENE-HBV...